Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FKJH5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,864
Award facts
- Contract value 100% obligated
- $3,863.68 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $3,863.68 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nucala 100 mg/mL auto-injector units. The award, issued on December 31, 2025, with an ultimate completion date of January 2, 2026, is structured as a firm fixed-price delivery order with no set-aside designation, indicating the vendor competed in open federal procurement. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring pharmaceutical supply needs across Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting capability as a critical supplier within the DOD pharmaceutical supply chain, holding a single-award IDC under the PPV-G GEN V program (contract SPE2DR) with a $499,999,999 ceiling value and completion date of December 31, 2036. The company's established performance record encompasses delivery of diverse pharmaceutical products including specialty biologics, oncology treatments, immunosuppressants, vaccines, and emergency medications. The current delivery order for Nucala, a biologic immunosuppressant agent, reflects the company's continued role in fulfilling specialized pharmaceutical requirements for military medical operations globally.
Quick answers
Who was awarded contract SPE2DR26FKJH5?
SPE2DR26FKJH5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 31, 2025.
How much is contract SPE2DR26FKJH5 worth?
The government has obligated $3,864 on SPE2DR26FKJH5.
Is contract SPE2DR26FKJH5 an order under another contract?
Yes. SPE2DR26FKJH5 is a delivery order under SPE2DR25D9105, an indefinite delivery contract.
Was contract SPE2DR26FKJH5 competed?
The extent of competition for SPE2DR26FKJH5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award